Table 5.
Analysis | HPV DNA detection test or HPV type | Sample | No. (%) with positive results and cytological findings of: |
|||
---|---|---|---|---|---|---|
Normal | ASCUS | LSIL | HSIL | |||
Generic HPV DNA detection (n = 194) | HPV infectiona | Cervical | 92 (66.7) | 16 (80.0) | 25 (78.1) | 3 (75.0) |
Urine | 79 (57.2) | 15 (75.0) | 27 (84.4) | 3 (75.0) | ||
GP5+/GP6+ | Cervical | 49 (35.5) | 13 (65.0) | 19 (59.4) | 3 (75.0) | |
Urine | 44 (31.9) | 9 (45.0) | 14 (43.8) | 1 (25.0) | ||
MY09/11 | Cervical | 53 (38.4) | 12 (60.0) | 21 (65.6) | 0 (0.0) | |
Urine | 50 (36.2) | 10 (50.0) | 11 (38.4) | 1 (25.0) | ||
pU1M/2R | Cervical | 50 (36.2) | 10 (50.0) | 17 (53.1) | 2 (50.0) | |
Urine | 36 (26.1) | 7 (35.0) | 16 (50.0) | 2 (50.0) | ||
Type-specific distributionb | HPV-16 | Cervical | 64 (69.6) | 9 (56.3) | 14 (56.0) | 17 (60.7) |
Urine | 45 (57.0) | 9 (60.0) | 3 (100.0) | 22 (73.3) | ||
HPV-18 | Cervical | 39 (42.4) | 2 (12.5) | 16 (56.0) | 2 (66.7) | |
Urine | 25 (31.7) | 8 (53.3) | 7 (25.9) | 1 (33.3) | ||
HPV-31 | Cervical | 38 (41.3) | 8 (50.0) | 17 (60.0) | 1 (33.3) | |
Urine | 24 (30.4) | 7 (46.7) | 7 (25.9) | 0 (0.0) | ||
HPV-33 | Cervical | 24 (26.1) | 3 (18.8) | 12 (48.0) | 1 (33.3) | |
Urine | 16 (20.3) | 2 (13.3) | 5 (18.5) | 1 (33.3) | ||
HPV-45 | Cervical | 7 (7.6) | 3 (18.8) | 5 (20.0) | 0 (0.0) | |
Urine | 12 (15.2) | 5 (33.3) | 5 (18.5) | 1 (33.3) | ||
HPV-58 | Cervical | 24 (26.1) | 3 (18.8) | 11 (44.0) | 1 (33.3) | |
Urine | 26 (32.9) | 6 (40.0) | 11 (40.7) | 2 (66.7) |
HPV infection was considered positive when the PCR results using any of the three primer sets were positive.
Categories involved less than 194 women, given that only women identified as being infected with HPV were included in the type-specific identification reactions, meaning that n values for each diagnostic category varied for the HPV types. Type-specific identification was determined by independent PCRs using type-specific primer sets.